Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer
References (101)
- et al.
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
Mol Cell
(2003) - et al.
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell
(2004) - et al.
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
Int J Radiat Oncol Biol Phys
(2004) - et al.
Insights into ErbB signaling from the structure of the ErbB2- pertuzumab complex
Cancer Cell
(2004) - et al.
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
Ann Oncol
(2002) - et al.
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
Immunol Lett
(2006) - et al.
The ErbB signaling network: receptor heterodimerization in development and cancer
Embo J
(2000) - et al.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Science
(1987) - et al.
Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling
Mol Biol Cell
(2002) - et al.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
N Engl J Med
(2001)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
Oncogene
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
Oncogene
Therappeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression
Breast Cancer Res Treat
Monoclonal antibody to HER- 2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
Cancer Res
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
Cancer Res
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
J Clin Oncol
Phase II study of receptor- enhanced chemosensitivity using recombinant humanized antip185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
J Clin Oncol
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
N Engl J Med
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
J Clin Oncol
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
N Engl J Med
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Lancet
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
Oncogene
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors
Breast Cancer Res Treat
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
J Natl Cancer Inst
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
Oncologist
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
J Clin Oncol
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4- expressing breast cancer cell line
Cancer Res
Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance
Int J Cancer
NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
Cancer Res
The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage
Oncogene
The biology and clinical relevance of the PTEN tumor suppressor pathway
J Clin Oncol
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
J Natl Cancer Inst
Lapatinib: current status and future directions in breast cancer
Oncologist
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer
Cancer Res
A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
Cancer Res
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
Oncogene
Lapatinib induces apoptosis in trastuzumab- resistant breast cancer cells: effects on insulin-like growth factor I signaling
Mol Cancer Ther
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen- resistant breast cancer
Cancer Res
Phase I clinical, biology, and pharmacokinetic study of the combination of GW572016 and capecitabine in patients with advanced solid tumors
Proc Am Soc Clin Oncol
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
N Engl J Med
Lapatinib (L) plus capecitabine (C) in HER2+ advanced breats cancer (ABC): genomic and updated efficacy data
J Clin Oncol
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
Clin Cancer Res
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
Cancer Res
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors
J Clin Oncol
[Web site]. A Phase 1/2 Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
Br J Cancer
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast
Cancer Res
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Natl Cancer Inst
Cited by (33)
Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR
2022, Biochemical and Biophysical Research CommunicationsCitation Excerpt :However, trastuzumab resistance is an urgent clinical issue. About 20% of patients who initially receive trastuzumab develop metastatic tumors within 1 year [6,7]. Furthermore, tumors recur in more than half of patients with metastatic HER2-positive breast cancer who resistant to trastuzumab [8].
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib
2020, Cancer LettersCitation Excerpt :Amplification and/or overexpression of the receptor tyrosine kinase HER2 occur in approximately 20% of breast cancer [1–3]. Although both Trastuzumab and Lapatinib provide considerable clinical benefits for HER2-positive breast cancer patients, a large fraction of the diseases display primary resistance to these inhibitors [2–5]. Furthermore, tumors that are initially sensitive to these drugs go on to adapt to HER2-targeted inhibition or develop acquired resistance in patients with advanced diseases [2–5].
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
2018, Nanomedicine: Nanotechnology, Biology, and MedicineRadioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons
2017, Advanced Drug Delivery Reviews
This article includes discussion of investigational and/or unlabeled uses of drugs, including the use of trastuzumab as monotherapy, plus lapatinib, or plus docetaxel with or without carboplatin for the neoadjuvant treatment of breast cancer; trastuzumab plus either pertuzumab, HKI-272, gefi tinib, anastrozole, letrozole, bevacizumab with or without docetaxel, or lapatinib with or without paclitaxel for the treatment of advanced or metastatic breast cancer (MBC); lapatinib as monotherapy for the adjuvant treatment of breast cancer; pazopanib or lapatinib with or without pazopanib or letrozole for MBC or advanced breast, ovarian, endometrial or other solid tumors; 17-AAG, HKI-272, or CI-1033 for locally advanced breast cancer, MBC, or other solid tumors; or gefi tinib with anastrozole for the neoadjuvant treatment of breast cancer.
Dr Piccart has no relevant relationships to disclose.